Ascendis Pharma A/S (ASND) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Hellerup, Denmark. The current CEO is Jan Moller Mikkelsen.
ASND has IPO date of 2015-01-28, 1,017 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $15.34B.
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Hellerup, Denmark, dedicated to developing innovative therapeutics for unmet medical needs. The company's commercial product, SKYTROFA, treats growth hormone deficiency in patients, while its robust pipeline includes TransCon-based therapies targeting pediatric and adult growth hormone deficiency, hypoparathyroidism, achondroplasia, and various oncology indications. Founded in 2006, Ascendis leverages its proprietary TransCon technology platform to extend the duration and improve the efficacy of therapeutic proteins across multiple disease areas.
